eligibility_summary
Eligible: adults (≥18) with severe asthma per GINA who have received biologic therapy for asthma (even a single dose). Exclude: patients with other significant respiratory diseases, such as TB-destroyed lung parenchyma, prior lung resection, or lung cancer.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Design: Multi-center retrospective observational study of adults with severe asthma in Hong Kong who previously received biologic therapy (2003–Jan 2024), no interventions are given. Drugs/interventions: Real-world use of asthma biologics (monoclonal antibodies), including classes such as anti-IgE (e.g., omalizumab), anti-IL-5 (mepolizumab/reslizumab) and anti-IL-5Rα (benralizumab), anti-IL-4Rα (dupilumab, blocking IL-4/IL-13), and anti-TSLP (tezepelumab). Mechanisms: neutralize IgE to prevent FcεRI cross-linking, block IL-5 or IL-5Rα to suppress/deplete eosinophils (ADCC with benralizumab), inhibit IL-4/IL-13 signaling to reduce type 2 inflammation, block TSLP to dampen upstream alarmin signaling. Targets: IgE–FcεRI pathway on mast cells/basophils, eosinophils/IL-5 axis, Th2 cells/ILC2 and airway epithelium via IL-4/IL-13, epithelial–dendritic–ILC2 axis via TSLP. Outcomes: usage patterns, effectiveness, safety, biomarkers, lung function, exacerbations, steroid exposure.